Notice NOT-AI-22-027 from the NIH Guide for Grants and Contracts

Notice NOT-AA-22-007 from the NIH Guide for Grants and Contracts

Notice NOT-AA-22-006 from the NIH Guide for Grants and Contracts

Notice NOT-AA-22-005 from the NIH Guide for Grants and Contracts

Notice NOT-AA-22-004 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-MH-22-111 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) supports systematic and scalable approaches to profile the biological function of genes with an excess of damaging mutations in patients with neurodevelopmental and psychiatric disorders. Current understanding of the relationship between genetic and phenotypic variation is limited and one of the main bottlenecks in translating disease-associated genes to biology lies in the lack of scalable experimental platforms that can extend the unbiased nature of gene discovery to the discovery of biological mechanisms. This concept will attempt to fill that gap while also providing a bridge between existing NIMH efforts such as PsychENCODE and Convergent Neuroscience. New technologies and approaches are now making it possible to systematically implement high-throughput assays to determine how disease-linked genetic variation impacts neural function across biological levels of organization. This initiative proposes a series of FOAs to support the large-scale implementation of high-throughput assays to interrogate the molecular, cellular and physiological function of hundreds of disease-associated genes in parallel. A combination of full-scale and pilot projects will form a consortium for broad characterization of risk genes across an array of endpoints relevant to CNS function using a variety of experimental platforms (e.g., cellular, organismal). A consortium coordination center (CCC) will serve as a central hub providing administrative coordination across projects, including data and tools harmonization, development of an open-source portal to create a unified dataset and creating a standardized set of biological resources for use by the research community.

Funding Opportunity RFA-MH-22-110 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) supports systematic and scalable approaches to profile the biological function of genes with an excess of damaging mutations in patients with neurodevelopmental and psychiatric disorders. Current understanding of the relationship between genetic and phenotypic variation is limited and one of the main bottlenecks in translating disease-associated genes to biology lies in the lack of scalable experimental platforms that can extend the unbiased nature of gene discovery to the discovery of biological mechanisms. This concept will attempt to fill that gap while also providing a bridge between existing NIMH efforts such as PsychENCODE and Convergent Neuroscience. New technologies and approaches are now making it possible to systematically implement high-throughput assays to determine how disease-linked genetic variation impacts neural function across biological levels of organization. This initiative proposes a series of FOAs to support the large-scale implementation of high-throughput assays to interrogate the molecular, cellular and physiological function of hundreds of disease-associated genes in parallel. A combination of full-scale and pilot projects will form a consortium for broad characterization of risk genes across an array of endpoints relevant to CNS function using a variety of experimental platforms (e.g., cellular, organismal). A consortium coordination center (CCC) will serve as a central hub providing administrative coordination across projects, including data and tools harmonization, development of an open-source portal to create a unified dataset and creating a standardized set of biological resources for use by the research community.

Notice NOT-EY-22-003 from the NIH Guide for Grants and Contracts

Notice NOT-MH-22-140 from the NIH Guide for Grants and Contracts

Notice NOT-HL-22-007 from the NIH Guide for Grants and Contracts

Notice NOT-OD-22-054 from the NIH Guide for Grants and Contracts

Notice NOT-DA-22-008 from the NIH Guide for Grants and Contracts

Notice NOT-AT-22-009 from the NIH Guide for Grants and Contracts

Notice NOT-MH-22-130 from the NIH Guide for Grants and Contracts

Notice NOT-DE-21-021 from the NIH Guide for Grants and Contracts

Notice NOT-HG-22-003 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-22-090 from the NIH Guide for Grants and Contracts. The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility.

Funding Opportunity PAR-22-091 from the NIH Guide for Grants and Contracts. The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility.

Funding Opportunity PAR-22-060 from the NIH Guide for Grants and Contracts. The purpose of the Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools is to stimulate basic and clinical research in educational institutions that provide baccalaureate or advanced degrees for a significant number of the Nation's research scientists, but that have not been major recipients of NIH support. REAP grants create opportunities for scientists and institutions otherwise unlikely to participate extensively in NIH research programs to contribute to the Nation's biomedical and behavioral research effort. REAP grants are intended to support small-scale research projects proposed by faculty members of eligible, domestic institutions, to expose undergraduate and/or graduate students at health professional schools or graduate schools to meritorious research projects, and to strengthen the research environment of the applicant institution. Eligible institutions must award NIH-relevant baccalaureate or advanced degrees in health professions and have received less than $6 million per year of NIH support (total costs) in 4 of the last 7 fiscal years. In this FOA, a college is a stand-alone entity and not a component of a university system.

Notice NOT-EY-22-002 from the NIH Guide for Grants and Contracts